The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by ...

Apogee Therapeutics, Inc. had promising results from its APG808 Phase 1b study show potential for every 2-month asthma ...

Studies have shown that GLP-1s reduce inflammation in the brain and regulate anxiety as well as depression. When insurance ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

The phase 2b trial compared four doses of temtokibart to placebo in 262 adults with moderate to severe atopic dermatitis, the ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

Ashley Lora joined an eczema clinical trial for DUPIXENT and paved the way for other Black women to try clinical trials.

Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in mild- ...

Once again, AbbVie dominates doctors’ ranking of makers of immunology meds. | Just like last year, the Skyrizi and Rinvoq ...

Q1 2025 insights from Corvus Pharmaceuticals highlight promising soquelitinib trial results, extended funding, and plans for Phase 2 trials.

Almirall continues to target peak Ebglyss sales of more than €450 million by 2030, in line with consensus estimates. Ilumetri ...